Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Alagebrium (ALT-711) and Cardarine (GW-501516) — mechanism, side effects, legal status, and pricing.
Alagebrium (ALT-711) is a thiazolium-derived non-peptide small molecule investigated as an advanced glycation end-product (AGE) crosslink breaker. It reached Phase I–III human trials (2001–2010) for diastolic heart failure and hypertension but was never approved; clinical development was discontinued around 2009 due to financial constraints. No validated human dose exists. Currently sold by research-chemical vendors for research use only.
Cardarine (GW-501516) is a synthetic small-molecule PPARδ agonist — not a SARM and not a peptide, despite gray-market marketing that groups it with SARMs. Developed by GSK and taken into human lipid trials, its clinical development was discontinued around 2007 after rodent carcinogenicity findings. It has no regulatory approval anywhere, is WADA-prohibited at all times, and is sold only as a gray-market research chemical.
Alagebrium (ALT-711)
Cardarine (GW-501516)
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Alagebrium (ALT-711)
Cardarine (GW-501516)
COA corpus from Disclosed Labs — independently tested batches only.
Alagebrium (ALT-711)
2
COAs
99.6%
Avg purity
2
Labs
Cardarine (GW-501516)
2
COAs
99.7%
Avg purity
1
Labs
Alagebrium reached Phase I–III human trials (2001–2010) under sponsor Alteon Inc./Synvista Therapeutics but was never approved. A 16-week open-label pilot in 23 elderly patients (21 completers) with diastolic heart failure showed reduced left ventricular mass and improved Doppler diastolic index (E') without change in blood pressure, ejection fraction, or exercise capacity. The SPECTRA trial (ALT-711 + hydrochlorothiazide in hypertension) was terminated; the BENEFICIAL trial (chronic heart failure) was completed but did not meet efficacy endpoints. Preclinical studies in non-diabetic hypertensive rats, aged dogs, aged monkeys, streptozotocin-induced diabetic rats, and diabetic mouse models demonstrated improved vascular/cardiac function, reduced aortic stiffness, decreased collagen crosslinking, and improved renal pathology. A 2-year rat toxicology study found liver alterations that prompted a temporary enrollment suspension pending review.
Completed GSK-sponsored human trials in low-HDL/dyslipidemia subjects (2.5–10 mg/day, 12 weeks) improved lipids (HDL-C +16.9%, triglycerides −16.9%, LDL −7.3%; Sprecher et al., 2012). GSK halted development around 2007 after a 2-year rodent carcinogenicity study reported tumors across multiple organs; a 2019 mouse study found GW-501516 accelerated colitis-associated colorectal cancer. A published human case report documented severe rhabdomyolysis and hepatotoxicity from self-administration. Never approved for any indication; not a peptide.
Alagebrium (ALT-711) and Cardarine (GW-501516) are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs